Cuban Sci. 2026, 7(1): 1–2
Published on 4 Oct 2026 PDF (321K)Antibody-mediated immune response to EGF delivered by hydroxyapatite nanoparticles: a strategy for long-term cancer
Yerandy Hechavarria Luna, María del Carmen Luzardo Lorenzo
- Centro de Estudios de Proteínas (CEP), Facultad de Biología, Universidad de La Habana, La Habana, Cuba
- Laboratório de Bioinsumos – BIOLIDER, Novagrolider, Angola
- Laboratorio de NanoCancer, Centro de Inmunología Molecular (CIM), La Habana, Cuba
“CIMAvax-EGF controls circulating epidermal growth factor (EGF) through a vaccine-induced antibody response, but prolonged administration of mineral-oil adjuvants can cause tissue damage at the injection site and in adjacent areas. We evaluated the humoral immunogenicity and maintenance of anti-EGF antibodies elicited by hydroxyapatite nanoparticle (HANp) systems, showing sustained IgG responses, predominantly IgG1/Th2, and preservation of antibody levels after replacing CIMAvax-EGF maintenance doses with HANp–rhEGF–rP64k.”
References
- González-Martínez, D. A., et al. Hydroxyapatite Nanoparticles as a Potential Long-Term Treatment of Cancer of Epithelial Origin. ACS Applied Nano Materials 5, 6159–6170 (2022). https://doi.org/10.1021/acsanm.2c00021
- Saavedra, D., & Crombet, T. CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients. Frontiers in Immunology 8, 269 (2017). https://doi.org/10.3389/fimmu.2017.00269
- Lambert, S. L., Okada, C. Y., & Levy, R. TCR Vaccines against a Murine T Cell Lymphoma: A Primary Role for Antibodies of the IgG2c Class in Tumor Protection. The Journal of Immunology 172, 929-936 (2004). https://doi.org/10.4049/jimmunol.172.2.929
- Rodriguez, P. C., et al. Priming and Boosting Determinants on the Antibody Response to an Epidermal Growth Factor-Based Cancer Vaccine. Vaccine 26, 4647–4654 (2008). https://doi.org/10.1016/j.vaccine.2008.07.003
